Alzheimer’s closer to a Vaccine with new Slovakian Phase II Trial

23/06/2016 - 2 minutes

Axon Neuroscience is starting a Phase II trial with its immunotherapy for Alzheimer’s disease, which redirects the immune system against defective Tau proteins, thought to be the main cause of this major disease.

axon_neuroscience_phaseII_alzheimer_immunotherapyAlzheimer’s disease is the cause of up to 70% of dementia cases, according to WHO, which translates in over 30 million patients worldwide. As the world population ages, Alzheimer’s is quickly becoming a major global health concern.

While there’s still a lot of research going on to understand the exact root causes of Alzheimer’s, defective Tau proteins seem to be a definite hallmark of this and other neurodegenerative diseases (tauopathies).

One of the biotechs targeting Tau proteins is Axon Neuroscience (Slovakia), which already has a successful Phase I trial under its belt.

Now, Axon Neuroscience is taking its AADvac1 vaccine to Phase II trials. The 2-year trial will take place in Europe, enrolling 185 patients with mild Alzheimer’s disease.

Besides confirming the vaccine’s good safety profile,

This content is available exclusively to our paying members.

Our members receive the following benefits:

  • Unlock premium articles
  • Download our industry reports
  • Remove all banner ads
  • Access 1,500+ archived posts
  • Support our independent media
Already a member? Sign in
Do you want to remove this advert? Become a member!
Do you want to remove this advert? Become a member!

Support Us

Become a Member